Three non-small cell lung cancer patients who developed pulmonary thromboses during osimertinib treatment and could safely resume concomitant anticoagulation treatment: a report of three cases

BACKGROUND: Previous phase III study has demonstrated that osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor (TKI), exhibits superior antitumor effects compared to first-generation EGFR-TKIs and successfully prolonged overall survival (OS) in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoji, Satoshi, Watanabe, Satoshi, Hanazawa, Yusuke, Fujisaki, Toshiya, Kikuchi, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830264/
https://www.ncbi.nlm.nih.gov/pubmed/36636419
http://dx.doi.org/10.21037/tlcr-22-419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830264/
https://www.ncbi.nlm.nih.gov/pubmed/36636419
http://dx.doi.org/10.21037/tlcr-22-419

Ejemplares similares